Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.
about
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosisDefective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosisSweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial dataAn international randomized multicenter comparison of nasal potential difference techniques.Nasal potential difference to detect Na+ channel dysfunction in acute lung injury.Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function.Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epitheliaAdvancing outcome measures for the new era of drug development in cystic fibrosis.Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.Nasal potential difference measurements to assess CFTR ion channel activity.Progress in cystic fibrosis and the CF Therapeutics Development NetworkCFTR pharmacology.Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis.Modified method to measure nasal potential difference.CFTR involvement in nasal potential differences in mice and pigs studied using a thiazolidinone CFTR inhibitor.Gene delivery to human sweat glands: a model for cystic fibrosis gene therapy.When and how ruling out cystic fibrosis in adult patients with bronchiectasis
P2860
Q24187139-B3BDC6FD-A55F-4997-AF7F-42EDFA713A4FQ28479231-C930CF26-8FF5-4A66-80BC-8F275ABC2BFDQ30784080-3BF1BF2D-709E-43A7-8979-2A7A1FB9EA80Q34184239-7211EEC2-D5A6-48AD-AFE8-D3CC47587DA6Q34720193-E2F52D98-BD60-481C-BE96-6884BF97A7AAQ34901567-908FE163-028A-4E28-A00F-228A7650FECEQ34989488-BF01E091-E30D-467B-8168-E61A57AEED74Q35627639-521CC2E6-8A78-497C-90C9-C38B197016BFQ35855342-24961D38-AD49-4B48-BB97-2E82179999DBQ36699974-CDDAD98D-F219-4F2C-A5C5-39DC763FEF30Q36891530-6ED04BB1-D3ED-4C94-9B98-4AADB784CFFFQ36891541-62E790CD-F25B-4BFC-93E4-77BB544C0F1AQ36999197-484231A1-324D-48EE-A074-A08418C92198Q37140714-E5C8F73B-7DA2-408A-BA17-1CECF6F4A661Q37209004-704CD6D2-8CC1-4540-8A50-987359F70E27Q38972431-AD371DE5-0069-455E-A275-9C0D5BE5985BQ42973495-F19D5595-220C-408E-BE59-DBAA54DA9E8AQ43861075-F4D90840-E9EC-4731-AA0F-76D08EE29019Q44361154-FE85578E-F06E-4EC3-A172-D662A5E3A1EAQ44972948-B5F2CE54-AB75-422B-B3E7-A97AC7C11E29Q45885230-E5623455-C7D2-474E-8AD8-0D0765F710A2Q58792962-C354A772-E10B-4F0A-9288-854181BC9AD7
P2860
Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Use of nasal potential differe ...... subjects with cystic fibrosis.
@en
Use of nasal potential differe ...... subjects with cystic fibrosis.
@nl
type
label
Use of nasal potential differe ...... subjects with cystic fibrosis.
@en
Use of nasal potential differe ...... subjects with cystic fibrosis.
@nl
prefLabel
Use of nasal potential differe ...... subjects with cystic fibrosis.
@en
Use of nasal potential differe ...... subjects with cystic fibrosis.
@nl
P2093
P2860
P356
P1476
Use of nasal potential differe ...... subjects with cystic fibrosis.
@en
P2093
Janice Launspach
Kathleen A Hilliard
Laura J H Milgram
Mark R Weatherly
Mary E Teresi
Michael W Konstan
Moira L Aitken
Nael A McCarty
Richard C Ahrens
Seung-Ho Han
P2860
P304
P356
10.1002/PPUL.10043
P577
2002-02-01T00:00:00Z